The Relationship between TRX-binding Protein-2 and Breast Cancer
|School||Kunming University of Science and Technology|
|Course||Biochemistry and Molecular Biology|
|Keywords||Breast Cancer Thioredoxin Thioredoxin binding protein-2 Taxol SB203580|
Breast cancer is one of the most common malignant tumor, the incidence rate of 10-22.7% of human malignancies, disease endanger women's health. China each year, about 40,000 people died of breast cancer, after cancer of the uterus. Studies have shown that breast cancer is the body, the result of the role of foreign multi-factor, but its pathogenesis is not entirely clear. This stage, surgery, radiation therapy, chemotherapy and biological therapy treatment of breast cancer, but a variety of treatments are subject to certain restrictions, so it is necessary to further study the pathogenesis of breast cancer, early prevention reduce breast cancer patient's pain and death thioredoxin redox regulation of protein commonly found in a variety of tissues, it has antioxidant, anti-apoptosis and promote cell growth and immune regulation. Thioredoxin binding protein-2 is a negative regulatory protein thioredoxin, it can with thioredoxin the active site of binding, inhibition of thioredoxin redox. Thioredoxin increased expression of thioredoxin binding protein-2 protein decreased expression or missing in many types of cancer tissue. Cyclooxygenase is a rate-limiting enzyme in the metabolism of arachidonic acid, cyclooxygenase-2 inhibition of apoptosis, raised the role of vascular endothelial growth factor expression was significantly higher in cancer tissue. The study by Western blot and real-time PCR amplification methods to detect the clinical breast cancer tissues and adjacent tissues in thioredoxin protein, thioredoxin binding protein-2, and cyclooxygenase-2 expression ; and breast cancer cell line MCF-7 cells with paclitaxel prove paclitaxel induced thioredoxin binding protein-2 expression signaling pathways. The results showed: increased thioredoxin cyclooxygenase-2 expression in breast cancer tissue compared with adjacent tissues, and thioredoxin binding protein-2 expression decreased; p38 mitogen-activated protein kinase inhibitor SB203580 inhibition of MCF-7 cells induced by paclitaxel thioredoxin binding protein-2 expression increased. The experimental results show the close relationship between thioredoxin and thioredoxin binding protein-2, and cyclooxygenase-2, and all these three breast cancer related; thioredoxin binding protein-2 in Taxol anticancer effects play an important role in paclitaxel through p38 mitogen-activated protein kinase pathway in thioredoxin binding protein-2 expression in MCF-7 cells, thus inhibiting the growth of tumor cells. The study further clarify paclitaxel to inhibit the growth of breast cancer cells, the molecular mechanism of thioredoxin binding protein-2 as a new therapeutic targets of breast cancer provides a theoretical basis.